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Background and objectives 
Human research ethics statements support equitable inclusion of diverse groups. Yet older people 
are under-represented in clinical research, especially those with impaired decision-making capacity. 
The aim of this study was to identify perspectives and experiences of older persons and their 
caregivers of research participation with impaired decision-making capacity. 
Research design and methods 
Scoping review of literature and online sources in January-February 2019 (updated June 2020) 
according to Joanna Briggs Institute methodology and PRISMA Extension for Scoping Reviews. 
English-language peer-reviewed research articles and Australian online narratives were included. 
Data were tabulated and narratively synthesized. 
Results 
From 4171 database records and 93 online resources, 22 articles (2000-2019, 82% United States, 16 
first authors) and one YouTube webinar (2018) were initially included; updated searches yielded an 
additional article (2020) and YouTube webinar (2020). Studies were heterogeneous in terminology, 
methods and foci, with hypothetical scenarios, quantitative analyses and examination of proxy 
consent predominating. Participants (n=7331) were older persons (71%), caregivers of older persons 
with dementia/cognitive impairment (23%) and older persons with dementia/cognitive impairment 
(6%). Synthesis identified two themes: willingness to participate and decision-making approaches. 
Discussion and implications 
Research participation by older persons with dementia may be optimized through reducing risks and 
burdens and increasing benefits for participants, greater consumer input into study development, 
and shared and supported decision-making. Older persons’ and caregivers’ perspectives and 
experiences of research participation with impaired decision-making capacity require investigation in 
a greater range of countries and conditions other than dementia, and dissemination through more 
varied media. 
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Background and objectives 
Research seeking to improve health, function and quality of life requires representative samples. Yet 
older persons are under-represented in research relevant to their needs, especially those with 
impaired decision-making capacity (Ridda, MacIntyre, Lindley, & Tan, 2010). Research exclusion of 
this group of older persons impairs external validity of many clinical studies, reducing opportunities 
to equitably build evidence for the benefits and harms of healthcare interventions (Ries, Thompson, 
& Lowe, 2017). 
This selection bias is multi-factorial. Informed consent and valid outcome measurement are more 
challenging when cognitive or communication impairments are present (Ridda et al., 2010). 
Researchers may lack pre-requisites to tailor methods and measures and instead use exclusion 
criteria to circumvent the challenges. Older people are often stigmatized, even more so when 
cognitive impairment is present (Evans, 2018), or considered too vulnerable for research 
participation (Bracken-Roche, Bell, Macdonald, & Racine, 2017). When proxy consent is used, proxy 
decision-makers (i.e. the person permitted by law to make decisions on behalf of another) may be 
uncertain of or disagree with the other’s preferences (Reamy, Kim, Zarit, & Whitlatch, 2013). 
International and national human research guidance supports equitable inclusion of diverse groups, 
yet varies in explanation and categorization of relevant ethical principles and processes (Canadian 
Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, & Social 
Sciences and Humanities Research Council of Canada, 2014; Dobson, 2008; "International Ethical 
Guidelines for Health-related Research Involving Humans, Fourth Edition," 2016; National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978; The 
National Health and Medical Research Council, Australian Research Council, & Universities Australia, 
2007 (Updated 2018)). Jurisdictional statutes and research ethics committees use different terms, 
definitions, degrees of inclusiveness and permissible consent processes, with some more restrictive 
than the overarching guidance (Ries et al., 2017). Individual reviewers, researchers, ethics 
committee members and clinicians also vary in attitudes, knowledge and practice regarding research 
inclusion of people with impaired decision-making capacity (Prusaczyk, Cherney, Carpenter, & 
DuBois, 2017; Ridda et al., 2010).  
Given this complex landscape, the aim of this study was to identify what is known about older 
persons’ and their caregivers’ perspectives and experiences of research participation for those with 
impaired decision-making capacity. The primary objective was to review relevant international peer-
reviewed research literature on the topic. To inform future local initiatives to improve research 
participation by older people with conditions impacting decisional capacity, the second objective 





A scoping review of published literature and online sources, according to Joanna Briggs Institute 
methodology (The Joanna Briggs Institute) and PRISMA Extension for Scoping Reviews (PRISMA-ScR). 
(Tricco et al., 2018). 
Search strategy 
We performed a database search of international literature in January 2019 in Medline, CINAHL, 
Cochrane, EMBASE, Web of Science and PsycInfo, using relevant terms for the participants (older 
people and caregivers) and concepts of interest (conditions affecting cognition; research 
participation; perspectives and experiences), with a lateral search of references of identified 
relevant articles. In February 2019, we searched websites of 30 pertinent Australian health advocacy 
organisations (nominated by investigators) for relevant narratives. Lastly, a Google search on 
February 11, 2019 for additional relevant webpages with eligible narratives, with the limit set to 
Australia and browsing history cleared before each new search. Reviewers appraised Web pages of 
each Google search against eligibility criteria and followed potentially relevant links until 10 
consecutive ineligible ones were found. YouTube video lists were systematically scrolled, potentially 
eligible videos identified and further relevant links pursued, for a maximum of one hour per search 
term (Luckett et al., 2016). All searches were repeated in June 2020. 
Full details of the search terms and websites are reported in Supplementary file 1. 
Selection criteria 
Included data sources were: i) research articles reporting perspectives and/or experiences of older 
persons (including those with and without cognitive impairment) and their caregivers of 
participating in research with impaired decision-making capacity, published in international English-
language peer-reviewed journals with no date limitations; and ii) relevant online narratives (e.g. 
blogs, chats and/or commentaries, spoken or written) by older persons or their caregivers on 
Australian websites. Sources primarily reporting professional advocates’, health carers’ or 
researchers’ perspectives of the topic, or not reporting a majority (i.e. <50%) of older participants 
and/or caregivers or age of the sample, were excluded. 
Data charting and synthesis 
Database search results were imported into Endnote X7 then Covidence (www.covidence.org, 
Veritas Health Innovation Ltd.) One reviewer [AG] applied eligibility criteria to all titles and abstracts 
with others performing the second independent screen [AH, SK, CS, AC, IAD, LX]. Two reviewers [AH, 




through discussion [AH, LE, SK, CS, AG]. LE extracted data relevant to study authors, country of 
origin, aims, design, sample, methods and results into an Excel V15.28 spreadsheet, AH undertook 
independent checking, and discrepancies were resolved by discussion [LE, AH, SK].   
Four reviewers [AG, AH, AC, MV] extracted online narrative data relevant to the organisation, URL, 
focal health condition, target audience, country, date, type of commentary and its URL, title, author 
and content into a second Excel V15.28 spreadsheet. 
LE, AH and SK presented extracted and tabulated data to the full investigator team, consumers (i.e. 
people with lived experience of relevant health issues) (NHMRC, 2018) and researchers with topic 
expertise in a face-to-face/Zoom workshop in October 2019 to obtain ranging perspectives in 
interpretation. Of note, while no consumer who contributed to the study as an investigator [IG] or 
workshop participant had a condition that impaired their decision-making capacity, all were aged 
over 65 years and had experience of serious or chronic illness and/or caring for a family member 
with dementia or other life-limiting conditions.  
Ultimate reporting of results was via summation of source and participant characteristics, summary 
tables, and narrative synthesis of all findings (Popay et al., 2006), using source terminologies and 
rounding of quantitative results to whole numbers.  
In keeping with scoping review methodology, we did not assess included studies for risk of bias (The 
Joanna Briggs Institute; Tricco et al., 2018).  
Results 
From 4171 identified database records, we initially included 22 research articles by 16 first authors. 
Four first authors contributed to eleven articles (50%), one to seven (32%) and another was an 
investigator of this review [NR]. The first search of Australian websites identified 93 potentially 
relevant online resources, of which we included one: a 2018 YouTube webinar on dementia research 
Updated searches in June 2020 yielded one additional article (2020) and another YouTube webinar 
(2020). Overall, 23 research articles and two online sources were included (Figure 1). 
Characteristics of included sources 
Research articles 
Studies were conducted in the United States (US) (n=19), Canada (n=2), Australia (n=1) and Israel 
(n=1), published during 2000-2020. Sixteen (70%) included caregivers, 14 (61%) included participants 
experienced in proxy decision-making for an older person with dementia and nine (39%) included 




Of 7331 total participants, 5189 (71%) were older persons with no diagnostic information reported 
(mean age 76); 1685 (23%) caregivers of older persons with dementia/cognitive impairment (mean 
age 63); and 457 (6%) older persons with dementia/cognitive impairment (mean age 76). 
Dementia/cognitive impairment was variously ascertained and ranged in severity from mild to 
severe. Terminology for participants varied, with some articles using terms for persons with 
dementia that were seemingly contrary to more recent recommendations for “accurate, respectful, 
inclusive, empowering and non-stigmatizing” language ("Dementia Language Guidelines," 2018); for 
example, “demented patients” and “noncompetent” (Table 1).  
Studies were also heterogeneous in methodology and foci. Methods included: 
1. Structured interviews/questionnaires (n=11, 50%), with 1634 participants overall (901 older 
adults [262 with dementia or cognitive impairment] and 733 caregivers; mean sample 149 
[range 29-538]. Eight of these studies used structured tools to measure participants’ 
understanding, attitudes, illness severity and/or function (Table 2). All 11 were quantitative, 
with two incorporating qualitative analyses.  
2. Surveys (n=8, 36%), with 5486 participants overall (818 caregivers, 229 older persons at risk 
of dementia and 141 older persons with cognitive impairment; mean sample 686 [range 67-
1515]). 
3. Focus groups (n=2, 9%), with a combined total of 80 caregiver participants; mean sample 40 
[range 30-50]). 
4. Semi-structured interviews (n=2, 9%) with a total of 54 persons with dementia/cognitive 
impairment, 54 caregivers and 23 other older persons; mean sample 66 [range 33-98] 
Overall, fifteen articles (68%) reported perspectives of older persons towards consent and/or 
participation in hypothetical research with varying risk/burden and benefit, including trials of drugs, 
exercise and other interventions to treat dementia, genetic studies and brain donation after death. 
Ten studies (43%) were situated within ‘parent’ studies, mostly drug trials and population-based 
surveys.  
A summary of the included studies is presented in Supplementary file 2. 
Online sources 
The two online sources were webinar discussions. The first included a woman with Alzheimer's 
disease, her husband and carer, researchers, clinicians and pharmaceutical industry persons (total 
n=7), entitled “Let's Talk Dementia Research Webinar 1: Demystifying Trials, Access and 




dementia research” included a woman with frontotemporal dementia, a man with Lewy Body 
dementia, and the wife of a man with Alzheimer’s disease, along with three dementia researchers 
(total n=6) (NHMRC National Institute for Dementia Research, 2020).  
Narrative synthesis 
Synthesis of findings across sources is presented as two themes: willingness to participate and 
decision-making approaches. 
Willingness to participate 
Varying majorities were willing to support, participate, enrol another and/or agree to dementia-
related research with impaired decision-making capacity, and for consent to be provided by a proxy 
(most often a family member) (Ayalon, 2009; Bardach, Parsons, Gibson, & Jicha, 2020; Bravo, 
Paquet, & Dubois, 2003; Calamia, Bernstein, & Keller, 2016; Kim et al., 2009; Kim, Kim, McCallum, & 
Tariot, 2005; Ries, Mansfield, & Sanson-Fisher, 2019). Willingness to participate was positively 
associated with lower study risks and burdens (including less travel to study centers), perceived 
potential for benefit (direct and indirect), and positive research attitudes (Ayalon, 2009; Bardach et 
al., 2020; Bravo et al., 2003; Calamia et al., 2016; Dunn, Hoop, Misra, Fisher, & Roberts, 2011; 
Jefferson et al., 2011; Karlawish, Cary, Rubright, & Tenhave, 2008; Karlawish et al., 2009; Kim et al., 
2009; Kim et al., 2005; Ries et al., 2019). Feeling valued, more closely monitored, supported and/or 
mentally stimulated by the research team/process were reported as motivators or re-enforcers in all 
of the four qualitative studies (Austrom et al., 2011; Bardach et al., 2020; Connell, Shaw, Holmes, & 
Foster, 2001; Sugarman, Cain, Wallace, & Welsh-Bohmer, 2001); with one further reporting that 
participants valued the “positive and enjoyable” environment of the research center (Bardach et al., 
2020).  
Positive research attitudes almost always overcame the effect of other individual variables; including 
minority ethnicity of US participants (Ayalon, 2009; Kim et al., 2009; Kim et al., 2005), which without 
multivariate analyses was a significant variable or thought to require a tailored approach to 
recruitment (Connell et al., 2001; Jefferson et al., 2011; Stocking et al., 2006). Common motivations 
to participate were altruism, potential benefit for the person with dementia, and improved scientific 
knowledge (Alzheimer's Disease International, 2018; Austrom et al., 2011; Bardach et al., 2020; 
Bravo et al., 2013; Bravo et al., 2003; Calamia et al., 2016; Connell et al., 2001; Dunn et al., 2011; 
Jefferson et al., 2011; Ries et al., 2019; Sugarman et al., 2001). A greater range of influential 
circumstantial and relational factors was reported when decision-making was actual rather than 
hypothetical (Black, Wechsler, & Fogarty, 2013; Elad et al., 2000; Karlawish, Casarett, & James, 2002; 




decisions (Alzheimer's Disease International, 2018; Bardach et al., 2020; Elad et al., 2000; Sugarman 
et al., 2001). 
The online narratives by persons actively involved in dementia research (Alzheimer's Disease 
International, 2018; NHMRC National Institute for Dementia Research, 2020) revealed their 
willingness to participate was motivated by family history and legacy; hope; direct (e.g. improved 
physical and cognitive abilities during and after participating in a study of high intensity weight 
training: “One of the best things that has happened to me, by the way”) and indirect benefits (e.g. 
increased networks and opportunities to advocate for people with dementia); contributing to 
knowledge; and addressing unmet needs for people with dementia. For example:  
“Hope was important as I was concerned for my sons and grandchildren and future 
generations, especially since I had a genetic link. I also saw it as a worthwhile exercise as I 
had an interest in research methods.”  
One woman described how she became involved in research because she was mindful of her 
potential future experiences in residential aged care. Another stated she did so after her husband, a 
retired surgeon with Alzheimer’s disease, requested that she take him home so that he could 
resume watching a Stephen Hawking’s series about the universe instead of an organised activity that 
involved rolling balls down a slope. Two other narrators highlighted that many people with dementia 
require more than “balloon games and bingo” to maintain their abilities and quality of life. With 
regard to advocacy for others, one man recounted how his involvement in research led him to state 
in a presentation to a large group of stakeholders, “We have to remember that this is all about me, 
and 459,000 people living with dementia in Australia”. 
The narrators’ willingness to participate in research appeared resilient and yet, as in the included 
studies, was not absolute, as some outlined how researchers could improve the experience of 
participation by persons with dementia and their caregivers. They recommended using respectful 
language (with one narrator explicitly referring to an Australian guideline) ("Dementia Language 
Guidelines," 2018); person-centeredness; adopting a fighting rather than nihilistic attitude towards 
dementia; actively collaborating with people living with dementia in all stages of the study process; 
and providing appropriate information and support throughout studies, including at cessation 
(Alzheimer's Disease International, 2018; NHMRC National Institute for Dementia Research, 2020).  
Decision-making approaches 
While proxy research consent was the predominant focus, decision-making was also found to be 
highly diverse and multi-factorial (Black et al., 2013; Elad et al., 2000; Karlawish et al., 2002; 




persons, including the person with dementia, their proxy, other family members, clinicians and 
researchers, and it was not always clear who made (or should make) the ultimate decision (Austrom 
et al., 2011; Sugarman et al., 2001). There was imperfect congruence between older persons’ and 
proxies’ choices, with rates of agreement higher for those with supportive relationships and prior 
communication about research preferences (Black et al., 2013; Karlawish et al., 2002; Karlawish, 
Kim, et al., 2008). Hypothetical advance research directives were of interest to two cohorts, 
especially for lower risk studies (Karlawish et al., 2009; Ries et al., 2019). However, elsewhere 
advance documented preferences were also found no more congruent with current preferences 
than with surrogate predictions (Herault, Bravo, & Trottier, 2018).  
Informal caregivers who made health-care decisions for an older person with dementia were 
commonly the presumed (Ayalon, 2009; Kim et al., 2009) or preferred (Bravo et al., 2003; Ries et al., 
2019) future research proxies. Five studies reported participants gave proxies complete or partial 
leeway to override their current stated preferences in the future (Ayalon, 2009; Bravo et al., 2003; 
Karlawish et al., 2009; Kim et al., 2009; Stocking et al., 2006). Being willing to participate in research 
was positively associated with willingness to give proxies this future leeway (Ayalon, 2009; Bravo et 
al., 2003; Kim et al., 2009). Another four studies examined ethical standards guiding decision-
making, including best interests (seeking to maximise a person’s current well-being) and substituted 
judgement (making a decision that reflects what the person would choose if able to do so) (Dunn et 
al., 2013; Dunn et al., 2011; Karlawish, Kim, et al., 2008; Stocking et al., 2006). In these studies, more 
participants endorsed best interests, or best interest combined with substituted judgement, than 
substituted judgement alone. Proxies considered both past and present wishes of the person with 
dementia, often integrated best interests and substitute judgment considerations, and frequently 
prioritised what they thought matched the person’s current preferences and tolerances. Proxy 
decision-making operated and impacted upon spouses differently to children of older people with 
dementia (Bravo et al., 2013; Cary, Rubright, Grill, & Karlawish, 2015; Elad et al., 2000; Karlawish et 
al., 2009; Kim et al., 2009), and for those making decisions for persons with earlier stage dementia 
compared to later (Austrom et al., 2011; Sugarman et al., 2001).   
Discussion 
This scoping review identified that older persons’ and caregivers’ perspectives and experiences of 
research participation with impaired decision-making capacity have been predominantly studied in 
the US by a discrete group of researchers, focused on investigating dementia pathophysiology, 
prevention and cure and proxy decision-making via hypothetical scenarios and quantitative 




and an extensive online search of relevant Australian websites contained only two sources 
containing consumer perspectives on the topic. With these caveats, key findings were as follows. 
Most, but not all, persons in the included studies supported research participation with impaired 
decision-making capacity, especially if the study presented lower risk/burden and greater reward 
and if they themselves had a positive attitude to research. Preferences and decision-making were 
highly diverse, fluid and circumstantial. Proxy decision-making was often informally shared, and 
proxies sought to integrate best interests and substitute judgement considerations. Altruistic 
motivations by older people and proxies to advance knowledge, care, support and advocacy with 
regards to neurocognitive disorders suggested that affinity with a ‘community of illness’ (Barnbaum, 
2019) was another consideration in their research decision-making. The Australian online narratives 
by persons with dementia and their spouses added contemporary local perspectives that were 
congruent with findings of the included studies, as well as lending support to other calls to increase 
the involvement of persons living with dementia in research design, nomenclature and process 
(Bethell et al., 2018; "Dementia Language Guidelines," 2018). In the context of dementia, a 
progressive, life-limiting condition with no effective curative treatment, the finding that desperation 
also influenced decision-making about research participation further highlights the need for 
consumer contribution to study design and process, as well as circumspect presentation of potential 
benefits to prospective participants. 
Overall, factors influencing willingness to participate in clinical research were similar to studies 
pertaining to other life-limiting illnesses. A qualitative meta-synthesis of what influenced cancer 
patients to participate in drug trials reported similar factors: trust in physicians, attitudes of and 
consequences for family, hope of benefit, altruism, cost‐benefit considerations, availability of other 
options, attitudes towards living with cancer and as a way of coping with its psychological impacts 
(Nielsen & Berthelsen, 2019). A systematic review of perceptions of people receiving palliative care 
of research participation reported motivations were potential for personal benefit, altruism and 
desire to retain autonomy, and preferences were for lower risk and burden studies (White & Hardy, 
2010). Most recently, a 2019 international survey of 12,451 respondents (26% aged 65 or older) 
reported motivations to participate in clinical research were to help advance science and treatments 
and others with the disease, obtain better treatment or treatment education, and receive money; 
with older respondents more motivated by advancing science and helping others ("Perceptions and 
Insights Study: Deciding to participate," 2019). The commonality of findings about altruism, desire to 
contribute to knowledge, hope for benefit, and preference for safe and feasible studies is congruent 
with key human research advocacy for ethical inclusion of groups of persons who potentially are at 




"International Ethical Guidelines for Health-related Research Involving Humans, Fourth Edition," 
2016; National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research, 1978; The National Health and Medical Research Council et al., 2007 (Updated 2018)).     
Relevant to findings on approaches to consent for research participation is the movement from 
proxy decision-making to shared and supported decision-making approaches for people with 
disability (Australian Law Reform Commission, 2014; Sinclair, Field, & Blake, 2018). Shared decision-
making refers to the joint involvement of the person concerned and others involved in their life to 
reflect, respect and accommodate that person’s preferences, priorities and goals (Bunn et al., 2018). 
This includes situations where the person may require additional means to support their decision-
making. Shared decision-making incorporates the provision of evidence-based information, including 
via decision aids, with personal interaction and continuity of relationship (Bunn et al., 2018). In this 
approach, the question of who actually makes the decision is secondary to key persons engaging in 
the process together. In the clinical context, shared decision-making has resulted in better care and 
outcomes, including greater satisfaction and less conflict (Stacey et al., 2017). Development and 
testing of shared decision-making as an explicit research consent approach for older persons with 
impaired decision-making holds potential for better tailoring of information, consideration of the 
person’s preferences and values, reduction of decision-making burden on proxies, and guidance for 
researchers (Bunn et al., 2018; Clayman, Kumar, Murray, Mok, & Sharpe, 2019). 
A distinction of supported decision-making is that it privileges the person with disability as the 
decision-maker (Sinclair et al., 2018). This approach arose in Canada in the 1990s and has gained 
prominence in the context of the 2006 United Nations (UN) Convention on the Rights of Persons 
with Disabilities, which asserts that people with a disability can be enabled to make and 
communicate decisions affecting their lives (Sinclair et al., 2018). Recommendations of the 
Convention have been ratified and variously implemented by most UN Member States (Department 
of Economic and Social Affairs Division for Inclusive Social Development, n.d.). For example, in 2014 
the Australian Law Reform Commission (ALRC) developed National Decision-Making Principles to 
inform Commonwealth, state and territory laws and frameworks relevant to legal capacity 
(Australian Law Reform Commission, 2014). These are, in brief: equal right to decision-making and 
respect; obligation to provide necessary support for decision-making; person’s will, preferences and 
rights must direct decisions; and need for legal safeguards to prevent abuse and undue influence 
(Australian Law Reform Commission, 2014; Sinclair et al., 2018). No studies in the present review 
focused on supported decision-making. The absence of any findings regarding preferences for 
supported decision-making in research participation in this review may reflect the fact that this 




age-related cognitive impairments. We suggest that further research should more directly explore 
the potential role of supported decision-making in the process of consent for research participation 
(Haberstroh, Oswald, & Pantel, 2017).  
The ALRC considers decision-making solely by a proxy as last resort and proxy decisions should, to 
the extent possible, reflect the will and preferences of the person with disability (Australian Law 
Reform Commission, 2014; Sinclair et al., 2018). Current research guidance establishes various 
standards for proxies, referring to decisions that are in, or not contrary to, the person’s best 
interests (National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research, 1978), substitute judgment (Canadian Institutes of Health Research et al., 2014; Dobson, 
2008; "International Ethical Guidelines for Health-related Research Involving Humans, Fourth 
Edition," 2016), or an integrated approach. An example of the latter is within the Australian National 
Statement on Ethical Conduct in Human Research, which states a person with cognitive impairment, 
intellectual disability or mental illness unable to provide consent should have their wishes followed: 
“…unless changed circumstances mean that acting in accordance with those wishes would be 
contrary to the participant’s best interests.” (The National Health and Medical Research Council et 
al., 2007 (Updated 2018)).   
Findings of this review indicate that participants positioned respecting previous preferences of the 
older person with dementia as simply one or even a subordinate consideration among many others 
when actually making a research decision. This highlights how proxies’ likely intimate knowledge of 
the person uniquely positions them to communicate present wishes when that person can no longer 
do so independently. It also raises the question whether it is reasonable to expect proxies to make 
decisions based on a person’s prior expressed wishes without being influenced by actual research 
risks, burdens and benefits (for both the person and themselves), as the details and implications of 
the study under consideration would not have been known when the wishes were previously 
expressed. This finding also reflects the wider understanding of advance care planning as primarily 
“an ongoing process of reflection and communication with key others”, rather than a static directive 
(Ries, Mansfield, & Sanson-Fisher, 2020).   
Advance planning for research participation is yet to be fully implemented into practice. Of note, no 
standard advanced research directive (ARD) template or process currently exists. There is also 
evidence of researchers’ uncertainty and inexperience in aligning a person’s previously expressed 
research preferences, current wishes and circumstances, and proxy decision-making. For example, a 
recent survey of dementia researchers’ views on ARDs found that while the majority supported their 
use and almost all agreed that later dissent by the person overrode prior stated wishes, very few had 




be overridden by proxies. These researchers also expressed uncertainty about whether ethics 
committees/institutional review boards (IRBs) would accept an ARD as a valid expression of a 
person’s willingness to participate in research; and, conversely, some feared IRBs making them 
mandatory (Ries et al., 2020). Development of evidence, standards and practice for advance 
research decision-making is therefore required to inform IRBs, research teams and their interactions 
to best operationalize the practice. In these translation endeavors, older persons’ frequent 
prioritization of current preferences, circumstances and willingness to grant their proxies leeway will 
be important to consider. Where persons do not have anyone available or willing to be their proxy, 
ARDs, to the extent that these may be acceptable evidence of willingness to participate (e.g. for low 
risk activities), may help to overcome this particular barrier to research participation during 
decisional incapacity.   
Limitations 
Inclusion of only English-language research articles and Australian online narratives limits findings to 
high-income countries, particularly the US, which is a significant limitation given the majority of 
people with dementia live in lower and middle income countries (Prince et al., 2013). Risk of bias of 
included studies was not assessed, precluding systematic critique of overall strength of evidence. An 
inherent selection bias is possible due to sources representing mainly white persons, and likely those 
with more positive research attitudes (Hughes, Varma, Pettigrew, & Albert, 2015). Findings may not 
be generalizable to older people with non-dementia-related causes of impaired decision-making 
capacity, such as delirium or coma, or studies of other conditions.   
Conclusion 
This scoping review of international research literature and Australian online resources to identify 
older persons’ and caregivers’ perspectives and experiences of research participation with impaired 
decision-making capacity included 23 methodologically heterogeneous studies and two sources of 
online narratives. Predominant foci of included sources were dementia, proxy decision-making, 
hypothetical scenarios and quantitative methods. Findings highlight that research participation by 
older persons with dementia may be optimized through reducing risks and burdens and increasing 
benefits for participants, greater consumer input into study development, and investigation of 
shared and supported decision-making approaches. Older persons’ and caregivers’ perspectives and 
experiences of research participation with impaired decision-making capacity requires empirical 
investigation in a greater range of countries and conditions other than dementia, and dissemination 
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Table 1: Terms used for participants in included articles 
Participants Terms 
Older persons with no diagnostic 
information reported 
Older adults/older people/older Americans (n=7) 
Persons with dementia/cognitive 
impairment 
Older adults/persons/relatives*/family members* 
(with condition of interest) (n=7) 
Patients with (condition of interest) (n=5) 
Subjects (n=4) 
Decisionally incapacitated close relatives* (n=1) 
Noncompetent (n=1) 
Demented patients (n=1) 






Family members (n=4) 
Carers (n=1) 
Substitute health-care decision-makers (n=1) 
Legal guardians (n=1) 





Table 2: Structured measures used in included studies 
Structured measures Included studies 
Understanding of proposed study  
MacArthur Competency Assessment Tool for Clinical 
Research (MacCAT-CR) 
Dunn et al., 2013; Dunn et al., 2011; 
Karlawish et al. 2008; Karlawish, Kim, et 
al., 2008; Karlawish et al., 2002; 
Karlawish et al., 2009 
Attitudes  
Research Attitudes Questionnaire (RAQ)* Cary et al., 2015; Karlawish et al., 2009 
Social Responsibility Scale (SRS) Karlawish et al., 2009 
Health Care System Distrust Scale (HCSDC) Karlawish et al., 2009 
Intrinsic Religiousness Motivation Scale (IRMS) Karlawish et al., 2009 
Perceived Threat of Alzheimer’s Disease Scale (PTADS) Karlawish et al., 2009 
Function 
Activities of daily living (ADLs) Cary et al., 2015; Karlawish et al., 2008 
Instrumental Activities of Daily Living (IADLs) Karlawish et al., 2008 
Folstein Mini-mental State Examination (MMSE) Black et al., 2013 
Neuropsychiatric aspects 
Neuropsychiatric Inventory Severity subscale (NIS) Cary et al., 2015; Karlawish, Cary, et al., 
2008 
Neuropsychiatric Inventory Distress subscale (NID)  Karlawish, et al., 2008 
* Original RAQ was developed by Kim, and with further psychometric testing by Kim and two other first authors of included 
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Database records 
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Full-text articles 
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Figure 1: Flow chart of initial searches and inclusion Jan-Feb 2019  







Supplementary file 1: Search terms and websites 
Database searches 
Participants/Concepts Search terms 
Older people Humans/ AND Aged/ OR aged.tw. OR geriatric*.tw. OR older*.tw. OR elder*.tw. OR Frail 
Elderly/ OR Aged, 80 and over/ 
Caregivers  Humans/(MESH) AND Family/ (MESH) OR Caregiver/ (MESH) OR “carer” OR Legal guardians/ 
(MESH) 
Conditions affecting cognition Cognition*/ (MESH) OR Cognitive dysfunction/ (MESH) OR Dementia/ (MESH) or 
Frontotemporal dementia/ (MESH) OR "dementia vascular" OR Dementia Multi-infarct/ 
(MESH) OR Lewy body disease/ (MESH) or "dementia Senile" OR "dementia presenile" OR 
Delirium/ (MESH) OR deliri*" OR neurocognitive disorders" (MESH) OR “cognition disorders” 
(MESH) OR "Intellectual Disability" (MESH) OR “mental disorders” 
Clinical research participation Patient participation/ (MESH) OR Patient selection/ (MESH) OR Research ethics/ (MESH) OR 
Informed consent/ (MESH) OR “inclusion in clinical trials” OR Decision making/ (MESH) OR 
“patient activation” OR “patient empowerment” OR “patient involvement” OR “patient 
engagement” OR “shared decision making” OR “supported decision making” OR “supportive 
decision making” OR “participatory research” OR “process consent” OR “advanced research 
directive” OR “patient public involvement” 
Perspectives and experiences Health Knowledge, Attitudes, Practice/ (MESH) or Attitude*/ (MESH) or “views” or 
“perspectives” or “values” or “beliefs” or Qualitative research/ (MESH) or Focus groups/ 
(MESH) or Surveys and questionnaires/ (MESH) or “consumer”  
Website searches 
Organization Website 
ACT Public Trustee & Guardian https://www.ptg.act.gov.au/ 
Australian Clinical Trials Alliance https://clinicaltrialsalliance.org.au/ 
Brain Tumour Alliance Australia https://btaa.org.au/ 
Cancer Australia (and 14 supported 
Cancer Cooperative Trials Groups) 
https://canceraustralia.gov.au/ 
Cancer Council Australia https://www.cancer.org.au/ 
Cancer Voices Australia  https://www.cancervoicesaustralia.org/ 
Capacity Australia https://capacityaustralia.org.au/ 
CareSearch https://www.caresearch.com.au/Caresearch/Default.aspx 
Clinical Oncology Society of Australia https://www.cosa.org.au/ 




Consumers Health Forum of Australia https://chf.org.au/ 
Dementia Australia https://www.dementia.org.au/ 
Dementia Friendly Communities https://www.dementiafriendly.org.au/ 
Office of the Public Advocate (ACT) https://hrc.act.gov.au/public-advocate/ 
Office of the Public Guardian (NT) http://publicguardian.nt.gov.au/ 
Office of the Public Advocate (QLD) https://www.justice.qld.gov.au/public-advocate 
Office of the Public Guardian (QLD) https://www.publicguardian.qld.gov.au/ 
Office of the Public Advocate (SA) http://www.opa.sa.gov.au/ 
Office of the Public Advocate (VIC) https://www.publicadvocate.vic.gov.au/ 
Office of the Public Advocate (WA) https://www.publicadvocate.wa.gov.au/ 
Palliative Care Australia  https://palliativecare.org.au/ 
Parkinson’s Australia https://www.parkinsons.org.au/ 
Parkinson’s NSW https://www.parkinsonsnsw.org.au/ 




Step Up for Dementia Research https://www.stepupfordementiaresearch.org.au/ 
The Public Guardian (NSW) https://www.publicguardian.justice.nsw.gov.au/ 
Google searches 
Search 1 Research participation older people impaired decision-making capacity 
Search 2 Research participation older people cognitive impairment 
Search 3 Research participation older people dementia 




Supplementary file 2: Summary table of included studies  
Author, 
year 




US To compare older 
adults’ responses 
about participation in 
research with 
decisional incapacity 
with their documented 
preferences and 
surrogate predictions  
101 dyads within a RCT of ACP for health 
care and research: 
Older adults (n=101): 54% male; mean 
(SD) age 77 ± 4.5; mean (SD) schooling 
years 13 + 5; self-rated health excellent 
or very good 56% 
Self-selected surrogate (n=101): 21% 
male; mean (SD) age 71 ± 9.1; mean (SD) 
schooling years 12 + 4; relationship to 
older adult: spouse 74%, child 15%, other 
11%; 76% living with older adult 
Interviews with 3 vignettes of 
hypothetical studies (blood 
draw, physical exercises, drug 
trial) with older person’s current 
decisions about participation 
compared to their preferences 
documented 6 months 
previously + surrogate 
predictions of current decision.  
 
 93% hadn’t expressed their research preferences 
to surrogates 
 44% would be bothered “a little” or “a lot” by their 
surrogate making research decisions inconsistent 
with their wishes 
 Current preferences “modestly” aligned with both 
ACP preferences and surrogate predictions; neither 
was superior (52-70% alignment, depending on 
study) 
 ACP under-enrolled for blood draw study and over-
enrolled for physical exercise and drug trials; 
surrogates more often erred by under-enrolling  
Cary, 2015 US  To compare spousal vs 
non-spousal caregivers’ 
willingness to enroll a 
patient with AD in a 
trial and determine 
influence of research 
attitudes and caregiver 
burden 
Caregivers (n=103) of patients with 
probable AD (NINCDS-ADRDA 
Alzheimer's Criteria): 31% male; 
mean (SD) age 62.8 ± 14.8, range 32-87. 
Non-Latino 97%, White 78%; spouse 54%, 
adult child 46% 
Patients: 31% male; mean (SD) age 78 ± 
8.2, range 45-93 
Structured interviews with 
vignette of hypothetical AD drug 
trial; ranking of likelihood of 
participating; demographics, 
QoL, dementia severity, ADLs, 
brief NIS, caregiver burdens and 
RAQ. 
 
 35% definitely or probably would participate; 
36.9% possibly/might or might not/possibly would 
not; 28.2% probably or definitely would not 
 Willingness to enroll the patient positively 
associated with increased RAQ scores and being a 
spouse compared to being a child 
Dunn, 
2013 
US To examine whether 
and how proxies 
applied best interest 
and substituted 
judgement decision-
making approaches for 
hypothetical AD drug 
trials 
Proxy decision makers for patients with 
AD (proxy-reported) (n=40): 8% male; 
mean (SD) age 56.02 ± 11.2, range 36-86; 
relationship: adult child 75%, spouse 
10%, other 15% 
AD patients (n=40): 65% male; mean (SD) 
age 82.9 ± 6.5, range 65-97; Lived: alone 
15%, with others 45%, assisted living 
18%, board and care 3%, nursing facility 
18%, other 3%; Past research 
participation: yes 8%, no 92% 
Questionnaire + interviews of 
proxies randomly assigned to 
consent process for 1/4 
hypothetical AD drug trials of 
varying risks/benefits. 
Understanding assessed via 




 78% endorsed BI (described as used in daily life and 
maximizing QoL); 68% endorsed SJ (described as 
knowing patient’s values, honoring their wishes 
and prioritizing current preferences over past); 
49% endorsed both approaches (described as 
honoring preferences while weighing burdens and 
benefits) 
 In a forced-choice, 58% endorsed BI, 43% SJ 
 No variables (study type, perceived risk, stage of 




US To examine decision-
making by individuals 
asked to participate in 
Persons with Alzheimer’s, Parkinson’s or 
other dementia from the Consent for 
Dementia Research Study (included 
Semi-structured interview about 
who made the current research 
decision and how, reasons for 
 Subjects and surrogates often described current 
decision differently, diverse decision-making 




dementia research and 
their opinions on 




three drug and three non-drug studies) 
(n=39): 51% male; mean (SD) age 74.2 ± 
8.8; MMSE score >24 54%, 19-23 30.8%, 
<18 15%; mean (SD) years education 14.6 
+ 3.3; diagnosis: AD 67%, other dementia 
31%, mild CI 10%, depression 8% 
Surrogates (n=46): 74% male; mean (SD) 
age 63.1 ± 12.6; spouse 61%, 
son/daughter 22%, other relative 11%, 
non-relative 6%; mean (SD) years 
education 14.4 + 2.4 
participating, who should make 
future-research decisions and 
how (according to SJ, BI or 
something else). Eleven 
interviews abbreviated due to 
participant burden, inability to 
meaningfully respond or other 
communication difficulties. 
Illustrative quotes supplemented 
quantitative results 
 Reasons for participating: potential benefit for 
subject (74% subjects, 80% surrogates); help others 
in future (62%, 53%); trust in clinician/university 
(35%, 16%); help surrogates/family member (18%, 
40%); be informed of new treatments/other 
studies (6%, 11%); study required little of subject 
(6%, 7%); acceptable risks (5.9%, 4.4%); financial 
reasons (6%, 4%) 
 Future research decisions: 51% subjects nominated 
surrogates (mostly spouses), 39% nominated 
surrogates + other family members, 10% other 
family members; 55% surrogates (mostly spouses) 
nominated themselves; 73% of 33 pairs agreed 
 Preferred decision-making approach: BI (35% 
subjects, 42% surrogates); BI and SJ (18%, 20%), SJ 
(20%, 15%). 29% subjects and surrogates chose 
something else (e.g. impact on surrogate and/or 
other family members, feasibility of participating); 
six pairs agreed on approach (four BI, one 
combination BI and SJ, one SJ). For subjects with 




US To describe proxies’ 
reasons to enroll or not 
enroll a relative with 
AD in a hypothetical 
study 
Proxy and patient dyads (n=82) 
Proxies (n=82): 22% male; mean (SD) age 
70.2 + 12.1; spouse 73%, adult 
child/grandchild 22%, 
friend/friend/another caregiver 22%* 
Persons with AD or other dementia 
(proxy report of clinician diagnosis) 
(n=82): male 77%; mean (SD) age 79.6 + 
7.2; living with proxy 89%, assisted living 
4%, nursing home 2%, other 5% 
Semi-structured interviews of 
proxies randomly assigned to 
receive written information for 
1/3 hypothetical studies with 
varying risk and benefit 
(MRI/behavioral, drug, vaccine). 
Understanding assessed with 
MacCAT-CR, then asked whether 
or not they would enroll the 
person with dementia.  
 
 51% willing to enroll the person, 39% unwilling, 
10% unsure. MRI/behavioral study: 72% willing, 
24% unwilling, 3% unsure. Drug study: 52% willing, 
41% unwilling, 7% unsure. Vaccine study: 27% 
willing, 54% unwilling, 19% unsure. Willingness 
differed significantly across three protocols 
 Societal benefits: improved/targeted treatments, 
better understanding of treatment effects (66%); 
enhanced knowledge of disease/progression (38%); 
earlier/improved diagnosis, understanding of cause 
(9%); help others in future (general) (6%); slow 
progression (6%) 
 Personal benefits: improve symptoms (38%); 
altruism/future benefit (30%); medical 
evaluation/attention (21%); compensation (20%); 





 Reasons to enroll: altruism (35%), direct benefits 
(18%), trust in institution (6%); educational (6%) 
 Reasons to decline: inconvenience (38%), concerns 
about risks (27%) and lack of interest by the person 





To understand older 
adults’ understanding 
of and attitudes to 
enrolling non-
competent persons 
into AD research that 
does not benefit 
participants 
Adults > 65 years south-eastern 
Pennsylvania (n=538); 41% male; mean 
(SD) age 76.8 ± 6.7 
Structured interviews. 
Participants passing MacCAT-CR 
(93%) asked about willingness 
for proxy future research 
decisions and giving advance 
consent for two hypothetical AD 
studies (blood draw and blood 
draw + lumbar puncture) if they 
had AD. Those electing a proxy 
asked whether they would give 
them leeway to override 
advance consent. Other 
measures: SRS, HCSDS, RAQ, 
PTADS.  
 Most (96%) willing to designate proxy for research 
decision-making; 83% willing to give advance 
consent to blood draw study, 48% to lumbar 
puncture study  
 Most willing to grant leeway to proxies over 
advance consent (81% blood draw, 70% lumbar 
puncture)  
 For participants wanting a proxy, advance consent 
plus granting proxy leeway meant 92% would allow 
enrolment in blood draw study and 75% in lumbar 
puncture study, advance consent alone would have 
decreased enrolment to 83% and 52%, 
respectively.  
 Associations with greater willingness: blood draw – 
spouse/partner proxy, more years of education, 
less financial burden; lumbar puncture - higher 
RAQ score  
Karlawish, 
2008A  
US To identify how 
alterations in trial 
attributes improved 
study partners’ 
willingness to enroll 
their relative with AD 
Study partners (n=108): spouse 52%, 
adult child 44%; 38% male; mean (SD) age 
63 ± 14.5, range 32–87)  
Patients with probable AD (NINCDS-
ADRDA Alzheimer's Criteria; very mild to 
severe) enrolled in relevant trial: mean 
(SD) age 78 ± 8.2, range 45–93; dementia 
severity mean + SD, (range): NIS total (0–
36) 8.5 + 6.3 (0–27) and NID total (0–60) 
9.1 + 8.1 (0–42), basic ADLs (6–36): 9.3 + 
4.3 (6–26), IADLs (8–31): 20.7 + 6.0 (8–31) 
Structured interviews of study 
partners’ willingness to enroll 
relative with AD in 21-month 
hypothetical drug trial, 50–50 
probability drug vs placebo, 10 
study center visits, 2% risk of 
cardiac damage. Understanding 
assessed via MacCAT-CR. 
Participants’ reviewed eight trial 
designs with varying 
intervention risk, probability of 
placebo randomization, and 
location of and transportation to 
study visits and rated likelihood 
of allowing their relative to 
participate.  
 Higher risk decreased willingness to participate  
 All other attributes increased willingness to 
participate (low risk, home visits, 67–33 chance of 
drug) 
 Home visits increased willingness to participate 
most of all 
 Willingness to participate in a trial without 
amenities 17%; adding home visits 27%; low risk, 
home visits and higher chance of active treatment 
60%.  
 Value of reducing travel correlated with measures 






US To examine experience 
and views of patients 
with AD and their study 
partners on proxy 
consent to a trial 
Patients with mild-moderate AD 
(NINCDS-ADRDA Alzheimer's Criteria; 
MMSE 12-26) enrolled in AD trial at 
13/40 study sites (n=59): 46% male; 
mean (SD) age 72.2 ±9.2; education mean 
years + SD (range) 14.1 + 2.8 (6-20); 
White 92%, African American 8%; non-
Hispanic 97%  
Study partners (n=60): 43% male; mean 
(SD) age 64.3 ± 12.1; spouse 75%, 
education 15 + 2.8 (8-20); White 92%, 
African American 8%; non-Hispanic 95% 
Interviews of decision-making 
abilities via MacCAT-CR and 
psychiatric assessment, then 
about how study partners made 
decision to enrol the patient and 
attitudes towards proxy consent.  
 
 No difference in study partners of decisionally 
capable vs decisionally incapable patients 
agreeing or disagreeing patient made decision 
on their own; study partners of decisionally 
incapable persons more likely to agree patient 
left decision to proxy  
 85% study partners and 86% patients thought 
proxy consent was appropriate in general and 
for the patient 
 59% study partners would enrol patient based on 
BI; 24% on SJ; 17% thought BI and SJ essentially the 
same 
 Most resolved conflict between the two 




US To examine patients 
with dementia and 
their proxies’ views on 
ARDs and future proxy 
research decision-
making 
Patient and proxy dyads within the 
‘Planning Ahead Together’ (PAT) 
protocol44 (n=149) 
Patients with Alzheimer’s or other 
dementia (n=149): 38% male; mean 
(range) age 78.6, 52-94; MMSE mean 
(range) 19.8, 2-29; > high school 
graduation 53%; self-reported health 
status good or excellent 69%; African 
American 33%, White 67%  
Proxies (n=149)  
Separate interviews on previous 
research participation 
conversations with proxy, 
whether patients considered 
proxy the most trusted person 
for future decisions, and 
enrolment in five hypothetical 
studies of varying risk/benefit. 
Random dyads (n=69) 
participated in PAT protocol 
then talked to each other about 
earlier decisions.  
 
 Discomfort with proxy decision making: 33% 
patients; discomfort increased with increased 
study risks (e.g. 9% blood draw vs 27% 
intracranial stem cell implant); more African-
American respondents felt discomfort than did 
White (45% vs 27%). Reasons for discomfort: 
objection to study type (73%); autonomy 
(45%); problem with proxy (33%); need to 
confer with proxy (10%); proxy should share 
decision with others (8%). 16% patients with 
discomfort had previously discussed research 
participation with proxies compared to 30% 
without discomfort 
 Disagreement: 50% pairs disagreed in at least 
1/5 studies (1=38%, 2=13%, 3=5%, 4=3%); 48% 
patient willing/proxy unwilling; 52% patient 
unwilling/proxy willing. Mean MMSE score of 
patients with one or more disagreements with 
proxy were higher than for patients with no 
disagreements (22 vs 18) 
 After PAT protocol, 83% patients agreed proxy 
should make future research decisions based on 
what he or she thinks best at the time rather than 




patterns of resolutions included persuasion and 
assertion by either and planned future negotiation 
Karlawish, 
2002 
US To examine capacity, 
competency and 
reasons of patients 
with AD and their 
caregivers for enrolling 
in an early phase AD 
trial  
Patients with mild-moderate probable 
AD (NINCDS-ADRDA Alzheimer's Criteria) 
(n=15): mean (SD) age 72 + 8.1, range 56-
84 
Family caregivers (n=15): mean (SD) age 
64.9 (12.4), range 34–82 
Age- and education-matched non-
demented older persons (‘controls’) 
(n=15): mean (SD) age 77 ± 4.5, range 69–
86 to determine psychometric criteria to 
define capacity 
Structured interviews assessing 
capacity to consent via MacCAT-
CR and by experienced study 
coordinator (results not reported 
here), then reasons for enrolling 
or not enrolling in the trial and 
“How likely is it that your health 
will immediately improve as a 
result of participating in this 
research study?”  
 
 47% patients, 40% caregivers wanted to enroll; 
20% patients, 53% caregivers did not; 33% 
patients, 7% caregivers unsure   
 Reasons for enrolling: potential benefit to patient 
health/well-being, desire to help others and/or 
contribute to scientific knowledge 
 Reasons not to enroll: need to talk to other family 
before making decision, time commitment/burden, 
concerns about disrupting patient QoL, medication 
risks, potential physical or mental discomfort 
 Belief participation would improve health: ‘not at 
all likely’ 50% patients, 40% caregivers; ‘likely’ 33%, 
47%; ‘extremely likely’ 17%, 13%. Patients choosing 
at least likely had lower understanding scores than 
those choosing not at all likely  
Elad, 2000 Israel  To investigate factors 
affecting caregivers’ 
decisions to enroll or 
not enroll a demented 
patient in a drug trial  
Caregivers of “demented patients” of a 
memory clinic (n=29): 19 enrolled the 
patient in an experimental drug trial, 
spouse 63%, 10 declined, child 70% 
Patients (n=29): “mostly female”; mean 
age 73.3; European 86%, Asian or African 
7%, Israeli 7%; married 76%, widowed 





demographics; patient function, 
cognition and behavioral 
problems; trial participation 
decision-making; perception of 
caregiving role.  
 
 Enrolled patients “appeared” to have better 
function, cognition and emotional/mental 
condition 
 Reasons for enrolment: hope for patient’s 
improvement (63%), stabilize/maintain condition 
(47%), helped to maintain hope (21%), contribute 
to science (11%), physician recommendation (11%), 
family pressure (5%), sense of responsibility for 
patient (5%) 
 Reasons for declining: concern about side effects 
(60%), doubts about drug efficacy (50%), concerns 
for physical burden for patient (30%) or caregiver 
(20%), disagreement among family members 
(10%), bad previous research experience (10%). 
 Everyone consulted with others for the decision; all 
enrolling and 47% declining consulted with other 
family members; 21% enrolling and 20% declining 
involved the patient 
 Most thought they received adequate information 
about side effects (95% enrolling, 95% declining) 
and potential benefits (74%, 89%)  
 More declining caregivers were usually concerned 




in drug trials (70%), compared to 42% and 32% of 
enrolling caregivers, respectively 
 11% enrolled previously participated in a drug trial 
vs 60% non-enrolled 
 Most caregivers believed they had the right (72% 
enrolling, 80% non-enrolling) and obligation (61%, 
80%) to be responsible for the patient’s treatment; 
and most (95%, 80%) felt that they did almost 
everything they could for the patient. Feelings of 
burnout were higher in non-enrolling caregivers 
(60%) compared to enrolling (11%) 
Surveys 
Ries, 2019 Australia To examine views of 
older adults about 
willingness to be 




Older adults (n=174): 46% male; age 60-
74 n=126 (72%), > 75 n=48 (28%); high 
school or below n=94 (57%), 
trade/vocational training n=46 (28%), 
tertiary/university n=24 (15%); knew 
someone with dementia 116 (76%) 
(friend 37%, other relative 34%, parent 
21%, partner/spouse 8%). One (0.6 %) 
participant had dementia. 
Questions on willingness to be 
involved in future research with 
dementia, motivating factors, 
preferred substitute research 
decision-maker and advance 
research directives (ARD). 
 
 Over 90% agreeable to 12/13 research activities, 
less so for drug studies (60%) 
 Motivators: direct benefit (95%), could benefit 
others with dementia (94%); help scientists 
understand other diseases (90%) 
 Preferred substitute research decision-maker: 
substitute health-care decision-maker (88%), 
doctor/health professional on research team 
(78%), doctor/health professional external to 
research team (33%), independent legal body 
(29%) 
 79% very or somewhat interested in making an 




US To compare older 
adults’ interest in and 
beliefs about drug vs 
other interventions for 
AD and factors 
associated with lack of 
interest in drug trial 
Older adults from Louisiana and 
surrounding states enrolled in a 
longitudinal study of brain aging (n=67): 
36% male; mean (SD) age 70.4 ± 5.8, 
range 55–85. Cognitively healthy n=43 
(64%), with mild CI n=24 (36%) (cognitive 
status determined from most recent 
parent study assessment last 12 months; 
mild CI based on RBANS) 
 
Questions on current health, 
concerns about memory 
problems, interest in 
participating in studies with 
varying characteristics and 
beliefs about likely success of 
different interventions for 
chronic neurological diseases 
such as AD.  
 
 Potential benefit for self and others strongly 
associated with increased interest in participation 
 52% had decreased interest in drug trial with no 
significant individual predictors 
 Other study characteristics associated with 
decreased interest: receipt of lumbar puncture 
(68%) and daily (86%) or thrice-weekly (73%) study 
center visits 
 Drug interventions associated with greatest 
decreases in interest yet also thought more likely 
to be effective than meditation, acupuncture, yoga, 
computer-based interventions (but not exercise or 






Canada To identify factors 
influencing decisions to 
enroll a decisionally 
incapacitated close 
relative to a 
hypothetical study 
Laypersons (n=1063): 
Older adults (n=679): 57% male; mean 
age 75.2 ± 6.9; education: high school 
54%, < high school 20%, professional 
school/college 14%, university 12% 
Informal caregivers of decisionally 
incapacitated older adults (‘caregivers’) 
(n=384): 43% male; mean (SD) age 65.6 ± 
12 (31-88); education: high school 46%, 
university 22%, professional 
school/college 20%, < high school 12% 
Professionals:  
Physicians (n=495), researchers(n=177), 
IRB members (n=325) 
Survey questions about potential 
direct benefits, serious side 
effects and inconvenience to 
relative, potential benefits and 
inconveniences to relative, 
researcher reputation and 
potential benefit to others.  
 
 Higher proportion older adults (61%) chose 
prospect of direct benefits for relative 
 Laypersons less frequently chose likelihood of 
adverse events as most influential compared to 
professionals (20% vs. 40%)  
 Researcher reputation more frequently chosen by 
laypersons than professionals (9% vs 2%) 
 Fewer laypersons high ranked possibility of serious 
side effects for relative compared to professionals 
(57% vs. 87%)  
 Inconveniences to relative more often considered 
least influential by laypersons than professionals 
(52% vs. 33%) as was possibility of side effects (8% 
vs. 1%)  
 No variables associated with older adult choices  
 Caregiver younger age associated with being 
influenced by potential for serious side effects 
Jefferson, 
2011 
US To describe participant 
reasons for enrolling in 
an AD research registry 
and barriers, incentives 
and variables 
associated with 
enrolling in additional 
studies  
Older persons (n=235): male 40%; mean 
(SD) age 75.3 ± 8.1, range 58-99; 49% 
with mild CI (n=98) or dementia (n=18) 
(determined by procedures of 
the National Alzheimer’s Coordinating 





Satisfaction Scale, IRMS, HCSDS, 
RAQ.  
 
 Reasons for registry enrolment: advance AD 
research (56%), benefit family, friends, future 
generations (21%), personal concerns for memory 
(13%)  
 Barriers to study participation: insufficient time 
(30%), driving into city (28%), no transportation to 
research center (14%), no financial compensation 
for time (14%)  
 Incentives: transportation (61%), home visits 
(55%), compensation for time (50%)  
 Significant variables: Home-based visits endorsed 
by those who were older or had less formal 
education; non-White respondents more likely to 
endorse compensation as incentive; higher interest 
in participation correlated with higher RAQ score 
Kim, 2009  US 
 
To assess older 
Americans’ views on 
surrogate consent for 
dementia research of 
varying risk and benefit 
and willingness for 
surrogate leeway to 
Older persons within the 2006 Health 
and Retirement Study (n=1515): 42% 
male; 51-59 years 32%; 60–69 years 35%; 
70–79 years 20%; >80 years 12%; years of 
education < 12 51%; 13-15 24%, >16 24%; 
White 82%, Black 10%, Hispanic 6%, 
Other 2%; married 65% 
Randomized to 1/4 surrogate-
based research scenarios: 
lumbar puncture (n=374), new 
drug trial (n=398), vaccine 
(n=375), and first-in-human gene 
transfer neurosurgical (n=368) 
and asked whether society, one-
 For all scenarios, most believed society should 
allow family surrogate consent (68-83%), would 
themselves participate (57-80%) and would grant 
some or complete leeway to surrogates to 
override their stated preferences (55-67%)  
 Significant predictors of giving leeway to 
surrogates: being willing to participate, married, a 






self or surrogate should allow 
participation.  
 
transfer scenario (although not by those who 
considered religion very important) and feeling 





To evaluate public 
opinion about 
participation in AD 
research and 
willingness for proxy 
consent 
Persons aged > 50 years and their carers 
(any age) from 2006 Health and 
Retirement Study (n=1469): 42% male; 
ages 40-50 years 41%; 61-70 years 31%; 
>70 years 28%) 
Participants given information 
about AD and AD research; 
randomized to 1/4 
hypothetical studies with 
varying risks and benefits, 
questioned about wishes for 
proxy consent, whether society 
should allow families to make 
decisions in their place, degree 
of leeway given to close family 
members to go against their 
preference, socio-
demographics 
 Agreed to participate: 66%; agreed to proxy 
consent: 71%; give complete or some leeway to 
family members to go against their preferences 
(20% and 38%, respectively).  
 Only significant predictor of willingness to 
participate was research type: participants more 
likely endorsed moderate benefit/minimal risk 
and less likely endorsed minimal benefit/severe 
risk relative to minimal benefit/moderate risk.  
 Odds of agreeing to a proxy 9.42 times higher for 
those who had agreed to participate in research 
relative to those who refused 
Kim, 2005 US 
 
 
To explore views of 
older people at risk of 
dementia on surrogate 
consent for research 
Persons enrolled in an AD prevention 
trial, aged ≥70 years with at least one 
first-degree relative with probable 
dementia from four study sites (n=229): 
59% male; mean (SD) age 77.3 ± 3.9; high 
school < 19%, some college 28%, college 
27%, postgraduate 24%; 
spouse/significant other 66%, lives alone 
28%, other 5%; White 96%, Black 1%; 
Native American 0.4%, ethnicity not 
identified 3% 
Information on AD symptoms, 
history, treatments, need for 
research, consent issues. 
Questions about acceptability of 
surrogate based research from 
societal, first-person and 
surrogate perspectives for 10 
hypothetical studies of varying 
risk/benefit, risk categorization 
for each, RAQ, demographics, 
personal history.  
 Majority (54%-95% depending on study type) 
thought all 10 surrogate consent studies should 
definitely or probably be allowed by society  
 More responders supported surrogate consent for 
lower risk studies and drug RCT (90%) compared 
to brain biopsy (56%) and gene transfer studies 
(54%)  
 Acceptability of surrogate consent highest from 
first-person perspective, then societal, then 
surrogate (significant in 23/30 (77%) scenarios)  
 Higher RAQ score only significant covariate for 












Older adults (n=300): 35% male; mean 
(SD) age 73.9 + 6.7 
Informal caregivers of cognitively 
impaired patients (n=434): 22% male; 
mean (SD) age 57.4 + 11.9; 50% legal 
guardians)  
Professionals (n=234): 
Questions about knowledge of 
relevant Quebec legislation; 
opinions about who should 
make research participation 
decisions when the elder lacks 
decision-making capacity, for 
hypothetical studies with varying 
risk/benefit; acceptability of 
soliciting a person with 
cognitively impairment for 
 Previous research experience: older adults 11%, 
informal caregivers 26% 
 Overall: “few” respondents believed researchers 
could proceed without consent in any scenario; 
around 10%” thought cognitively impaired persons 
should not be solicited for research at all (30% for 
higher risk studies); most preferred a legal 
guardian and devoted relative or friend be 
involved; proportions favoring consent by just a 




Researchers (n=98) and members of 
institutional review boards (n=136) 
research; surrogate consent by a 
relative; socio-demographics and 
research experience.  
 Group differences: laypersons more often wanted 
a relative or friend involved for higher risk studies; 
less often supported inviting people with 
decisional incapacity to research; less often 
permitted future surrogate decision-making for 
oneself, compared to professionals  
 Associations of increased permissibility to 
surrogates: older adults who were male or more 
willing to participate in research; informal 
caregivers who previously made surrogate 
decisions or more willing for cognitively impaired 




US To understand what 
motivates individuals 
to become engaged 




Older persons who had participated in 
AD research at the Sanders-Brown 
Center on Ageing (n=28) and study 
partners (n=5): 55% male; mean (SD) age 
73.55 + 5.14; Black/African American 3%, 
White, non-Hispanic 94%, White, 
Hispanic 3%; Cognitively impaired 15%;  
mean (SD) number of clinical trials 2.58 + 
1 
33 face-to-face interviews 
focused on research 
participation motivations, 
experiences and views. Thematic 
analysis via constant 
comparative method. 
Activators: Awareness of Disease; Memory Problems 
and Concerns 
Motivators: Know early and Be Proactive; Help and 
Provide Hope; Help the Future and Contribute to 
Society 
Outside mediators: Opportunity, Awareness and Ease 
of Participation; Comfort with Research 
Re-enforcers: Monitoring; Coping and Support; 
Mental Stimulation; Feeling of Value; Positive and 
Enjoyable Environment  
Findings informed the “AMOR (activators, motivators, 




US To identify family 
caregivers of persons 
with FTD experience, 
attitudes, awareness, 
and understanding of 
research and brain 
donation 
Family caregivers (mostly spouse or 
adult child) (n=30): 17.2% male; mean 
(SD) age 58.1 ± 12.8, range 25-76.5 of 
persons with FTD: mean age at diagnosis 
62 years, range 47-89 
Participants recruited via Association for 
Frontotemporal Degeneration and  
had varying access to FTD caregiver 
support groups and clinical research 
programs according to geographical 
location 
Six semi-structured focus groups 
using a community-based 
participatory approach in three 
cities on experience with 
medical research, understanding 
of brain donation and its 
importance and effectiveness of 
communication with 
researchers. Grounded theory 
analysis. 
 Willingness to participate: interested and willing, but 
lacked knowledge of opportunities 
 When/how the issue of brain donation is raised: 
considered inappropriate at first clinical meeting or at 
end stage; best time second or third visit after 
diagnosis  
 Who initiates discussion about brain donation: no 
consensus  
 Who is involved in decisions about brain donation: 
early discussion would allow the person with FTD to 
make his/her wishes known; considered not 
appropriate to discuss the issue in front of person 




variability about who else (e.g. family, everyone 
involved, Rabbi) 
 Motivation for participating in brain donation: 
obtain a definitive diagnosis, familial risk information 
and advance scientific knowledge   
 Lack of effective communication: about procedure 
itself and what to do as death approaches 
Barriers to research participation:  inappropriate 
and/or unmet expectations of clinical care, 
uncertainty about religious faith positions on organ 




US To examine African-
American and white 
caregivers’ attitudes, 
decision-making and 
experiences of family 
members’ participation 
in AD research 
Caregivers of a family member with AD 
or dementing illness enrolled in 
longitudinal clinical research at the 
Michigan Alzheimer’s Disease Research 
Center (n=50): 38 whites and 
12 African Americans; 66.26% male; 
mean age 64; attended at least some 
college: 74% whites, 58% African 
Americans; spouse 63%, child 27%, other 
relative or friend 10%; mean time since 
first symptoms: 9 years 
Six focus groups by ethnicity on 
making a decision to participate, 
experience with research 
process and recommendations 
for improving the process for 
future participants. Two 
additional questions for African 
American participants on 
barriers to/increasing 
participation. Content analysis. 
 Benefits: Access to Diagnosis, Care, and Treatment; 
Helping others; Support Received from Research Staff 
 Barriers: No Direct Benefit; Procedures and Tests; 
Insufficient Time and Resources; Difficulty Accepting 
the Diagnosis; General Attitudes and Beliefs; 
Skepticism and Mistrust About Research in General 
and Specific Procedures 
Recommendations: Making Research Participation 




US To examine proxy 
research decision-
making and informed 
consent for patient-
subjects with dementia  
Proxy and patient pairs from six 
dementia-related studies (n=49): 46 
Caucasian, 2 African-American, one Asian 
Proxies (n=49): male 40.8%; spouse 
(n=39), child (n=8), other relative (n=2); 
patients with probable AD or other 
dementia (mild-severe) (n=49): male 
42.9%, mean age 70.4, range 56-88, 
MMSE score 7-29, mean (SD) 21.1 + 5.4  
Initial (n=49) + follow-up at 2-4 
months (n=46) semi-structured 
interviews about diagnosis, 
treatment, experience; 
recruitment, project, decision-
making, advice to others re 
enrolment; informed consent 
process; experience with 
research participation; trust. 
Thematic analysis.  
 Deciding to Participate: shared (63%), made by proxy 
(27%) or patient (16%) (clearly and consistently 
attributed in one third of cases). Proxies tended to 
attribute decision to the patient when in agreement 
or risk was low, but would veto participation if did not 
agree. Most proxies who made decision to participate 
believed it was what the patient would have wanted, 
including for indirect benefits e.g. to feel “important 
again” 
 Reasons for Enrolling: Clinical trials: hope for direct 
benefit, perception of nothing else available, 
desperation, and combined reasons (e.g. all of above 
plus hope of benefit for others); Genetic markers 
study (one-time blood draw in regular clinic visit): 
considered incidental, not interpreted as research, or 
forgotten. Reasons to participate were altruism, hope 




Abbreviations: ACP: Advance care planning; AD: Alzheimer’s disease; ADLs: Activities of Daily Living; ARD: advance research directive; BI: Best interests; CI: cognitive impairment; FTD: 
Frontotemporal dementia; HCSDS: Health Care System Distrust Scale; IADLs: Instrumental Activities of Daily Living; IRMS: Intrinsic Religiousness Motivation Scale; MacCAT-CR: MacArthur 
Competency Assessment Tool for Clinical Research; MMSE: Mini-mental State Examination; NIA: National Institute on Aging; NID: Neuropsychiatric Inventory Distress subscale; NINCDS-
ADRDA: National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association; NIS: Neuropsychiatric Inventory Severity 
subscale; OR: odds ratio; PTADS: Perceived Threat of Alzheimer’s Disease Scale; QoL: Quality of life; RAQ : Research Attitudes Questionnaire; RBANS: Repeatable Battery for the Assessment of 
Neuropsychological Status; RCT: randomized control trial SD: Standard deviation; SR: supplementary references; SJ: Substitute judgement; SRS: Social Responsibility Scale 
*Percentages totaled more than 100% but are reported here as within the article.
children and grandchildren, and trust in physician or 
institution (which sometimes overrode proxies’ desire 
to understand the study)   
Burden of Decision-Making on Proxies: Greater when 
there was higher study risk or invasiveness, and when 
dementia was mild or moderate (despite patient 
being able to participate somewhat in the decision) 
because it meant acknowledging the dementia. Lower 
when dementia was severe, as proxy was by then 





Supplementary file 3: Preferred Reporting Items for Systematic reviews and Meta-Analyses  
extension for Scoping Reviews (PRISMA-ScR) Checklist 
 
SECTION  ITEM  PRISMA-ScR CHECKLIST ITEM  REPORTED ON PAGE 
#  
TITLE  
   
Title  1  Identify the report as a scoping review.  Title page 
ABSTRACT  
   
Structured 
summary  
2  Provide a structured summary that includes (as 
applicable): background, objectives, eligibility 
criteria, sources of evidence, charting methods, 
results, and conclusions that relate to the review 
questions and objectives.  
pg. 3 
INTRODUCTION  
   
Rationale  3  Describe the rationale for the review in the context 
of what is already known. Explain why the review 
questions/objectives lend themselves to a scoping 
review approach.  
pg. 4 
Objectives  4  Provide an explicit statement of the questions and 
objectives being addressed with reference to their 
key elements (e.g., population or participants, 
concepts, and context) or other relevant key 
elements used to conceptualize the review 
questions and/or objectives.  
pg. 4 
METHODS  
   
Protocol and 
registration  
5  Indicate whether a review protocol exists; state if 
and where it can be accessed (e.g., a Web 
address); and if available, provide registration 
information, including the registration number.  
The protocol was not 
registered, as 
PROSPERO do not 
accept scoping review 
protocols. 
Eligibility criteria  6  Specify characteristics of the sources of evidence 
used as eligibility criteria (e.g., years considered, 





7  Describe all information sources in the search (e.g., 
databases with dates of coverage and contact with 
authors to identify additional sources), as well as 
the date the most recent search was executed.  
pg. 5 
Search  8  Present the full electronic search strategy for at 
least 1 database, including any limits used, such 
that it could be repeated.  
Supplementary file 1 
pg. 22 
Selection of sources 
of evidence†  
9  State the process for selecting sources of evidence 
(i.e., screening and eligibility) included in the 




10  Describe the methods of charting data from the 
included sources of evidence (e.g., calibrated forms 
or forms that have been tested by the team before 
their use, and whether data charting was done 
independently or in duplicate) and any processes 






Data items  11  List and define all variables for which data were 
sought and any assumptions and simplifications 
made.  
pg. 5-6 
Critical appraisal of 
individual sources 
of evidence§  
12  If done, provide a rationale for conducting a critical 
appraisal of included sources of evidence; describe 
the methods used and how this information was 
used in any data synthesis (if appropriate).  
NA 
Synthesis of results  13  Describe the methods of handling and 
summarizing the data that were charted.  
pg. 6 
RESULTS     
Selection of sources 
of evidence  
14  Give numbers of sources of evidence screened, 
assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally 
using a flow diagram.  
pg. 6-7; Figure 1 (pg. 
21) 
Characteristics of 
sources of evidence  
15  For each source of evidence, present 
characteristics for which data were charted and 
provide the citations.  
pg. 6-7 
Critical appraisal 
within sources of 
evidence  
16  If done, present data on critical appraisal of 
included sources of evidence (see item 12).  
NA 
Results of individual 
sources of evidence  
17  For each included source of evidence, present the 
relevant data that were charted that relate to the 
review questions and objectives.  
Supplementary file 2 
(pg.23-33) 
Synthesis of results  18  Summarize and/or present the charting results as 
they relate to the review questions and objectives.  
pg. 8-10 
DISCUSSION     
Summary of 
evidence  
19  Summarize the main results (including an overview 
of concepts, themes, and types of evidence 
available), link to the review questions and 
objectives, and consider the relevance to key 
groups.  
pg. 10-14 
Limitations  20  Discuss the limitations of the scoping review 
process.  
pg. 14 
Conclusions  21  Provide a general interpretation of the results with 
respect to the review questions and objectives, as 
well as potential implications and/or next steps.  
pg. 14 
FUNDING     
Funding  22  Describe sources of funding for the included 
sources of evidence, as well as sources of funding 
for the scoping review. Describe the role of the 
funders of the scoping review.  
pg. 2 
 
